Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Baxter International reported a revenue of $2.81 billion for the quarter ended June 2025, reflecting a year-over-year decline of 26.3% and an EPS of $0.59 compared to $0.68 a year ago, with revenue slightly below the Zacks Consensus Estimate of $2.82 billion, resulting in a surprise of -0.28% [1] Financial Performance - The company experienced a significant decline in net sales across various segments, with Pharmaceuticals in the U.S. reporting $187 million, which is a -5.1% change year-over-year and below the estimated $201.97 million [4] - International Pharmaceuticals net sales were $425 million, showing a +4.9% change compared to the previous year, but slightly below the estimated $434.72 million [4] - Healthcare Systems and Technologies International reported $205 million, exceeding the estimate of $198.81 million with a +3.5% year-over-year change [4] - Care and Connectivity Solutions International net sales reached $133 million, surpassing the estimate of $119.15 million, marking a +10.8% change year-over-year [4] - Overall, net sales for Pharmaceuticals totaled $612 million, slightly below the average estimate of $628.29 million, with a +1.7% year-over-year change [4] - Advanced Surgery net sales were $296 million, exceeding the estimate of $285.18 million, reflecting a +6.9% change year-over-year [4] - Other net sales surged to $111 million, significantly above the estimated $80.76 million, representing a remarkable +404.6% change year-over-year [4] - Front Line Care net sales were $293 million, slightly below the estimate of $299.81 million, with a -1% year-over-year change [4] - Infusion Therapies and Technologies reported $1.02 billion, below the estimate of $1.06 billion, with a -2% year-over-year change [4] - Medical Products and Therapies net sales were $1.32 billion, slightly below the estimate of $1.35 billion, with a -0.2% year-over-year change [4] Stock Performance - Baxter's shares have returned -9.9% over the past month, contrasting with the Zacks S&P 500 composite's +2.7% change, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]